Citi Research Reevaluates Bristol-Myers, Lowers Price Target By: Benzinga via Benzinga September 20, 2016 at 09:13 AM EDT Expectations are for an “underwhelming subgroup analysis” when the CheckMate-026 trial is presented at the forthcoming ... Read More >> Related Stocks: Astrazeneca Plc ADR Bristol-Myers Squibb Merck & Co Pfizer